he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
核对信源地址
上一页:梅干腹 脑裂畸形1例
下一页:羊角风的定义有哪些呢
- 2022-05-10脑瘤家庭护理方法有哪些
- 2022-04-202013年国际抗癫痫总会抗癫痫药使用指南
- 2019-04-18哪家医院治癫痫比较可靠
- 梅干腹 脑裂畸形1例
- FDA批准Aptiom用于治疗患者癫痫发作
- 肿痛的原因是什么? 肿痛的原因是什么?
- 什么是内陷?如何治疗?两个原因可能会暂时消失
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- 男人包皮太长,割好还是坏?也许很多人都理解错了
- 打开非那雄胺治疗增生的正确方法
- 北京大学人民医院第五届男性健康沙龙
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 寄生虫感染可能会增加儿童气道高反应的风险
- Blood:miR-146a缺失将IL6/TNFD诱导性炎症与髓系恶性有关
- 40岁以上的男性应警惕钙化
- 特发性癫痫大发作药物治疗的首选
- A&R:洛西汀对髋关节或膝关节骨性关节炎慢性疼痛患者没有附加值
- 谁说生不出娃娃 是女人的错!?
- 溢液的原因是什么?有些是按出来的!排毒吗?警惕血性溢液!
- 石头从哪里来?
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 打开窗户看见什么最吉利
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 骨质疏松症4项运动处方 1分钟自测法
- 不同类型的腰椎间盘突出症,如何识别和治疗?
- 首例新冠肺炎患者长期勃起异常
- 简单而不简单的疾病:经典输尿管结石 1 病例
- 癫痫的常见症状是什么?
- 男性应该如何避免精囊炎的侵袭?
- 女性月经量减少,可能是因为这件事,做2点,养子宫
- FDA批准首款用于增生的永久植入装置上市
- 痫患如何治疗 3大方法治疗癫痫患
- 药物难治性癫痫病征的神经调控治疗
- 癫痫病的治疗切除术
- 中国化疗癫痫病比较好
- 癫痫怎么确诊?只见你了解三大诊断手段
- 癫痫病权威治疗医院不可吃什么
- 左乙拉西坦治疗儿童局灶性癫痫安全必要
- FDA批准Aptiom用于治疗病症的癫痫发作
- 经期要注意 有些药物食品不应食
- 带鱼饭 带鱼不一样的吃法
- 惹来癫痫的病因
- 早期癫痫的表现是什么 讲述癫痫疾病的病因